Abstract: Protection of proteins against fibrillation may be afforded by introduction of certain histidine substitutions into the protein, such that a pair of histidines are present with sufficient spacing as to allow the histidines to coordinate with zinc. In the case of insulin, introduction of histidine residue substitutions at residues A4 and A8 together or a histidine residue substitution at residue B1, provides increased resistance to fibrillation while maintaining at least a majority of the activity of the insulin analogue. Introduction of a histidine residue substitution at residue A8 restores at least a portion of fibrillation resistance that may have been harmed by substitutions present on the B-chain such as those present in fast-acting insulins. Proteins protected by such histidine substitutions may be used to provide a pharmaceutical composition. A method of treating a patient includes administering a physiologically effective amount of the pharmaceutical composition to the patient.

Abstract: A thermoplastic composition having antimicrobial and good impact properties is disclosed. The composition comprises (i) (co)polycarbonate, (ii) (co)polyester, (iii) grafted elastomeric (co)polymer and an amount of an antimicrobial agent. The antimicrobial agent that contains zeolite, metal oxide and hydrotalcite is present in an amount sufficient to impart to the composition antimicrobial efficacy.

Abstract: A composition for use in treating or preventing a respiratory virus which comprises: (a) at least one water soluble zinc, copper, selenium and/or manganese compound able in aqueous solution to dissociate into zinc, copper selenium and/or manganese ions; (b) at least one water soluble ammonium agent able in aqueous solution to dissociate into ammonium ions (c) at least one acid, and (d) water.

Abstract: The disclosed subject matter provides a method for preparing a metal oxide, the method includes (a) contacting a metal salt precursor with an alcohol to provide a metal oxide; and (b) removing the metal oxide from the alcohol.

Abstract: The invention relates to chemical and pharmaceutical industry, in particular to developing ophthalmological agents having a wide spectrum of action based on vegetable components, vitamins, and trace elements. The agent for treating eye diseases comprises lyophilized blueberries, dihydroquercetin, beta-carotene, selexen, lutein, vitamins B1, B2, B6, and B12, and zinc. The agent having a wide spectrum of action exhibits a reparative, restorative (tonic) and regenerative effect, it does not have any irritating, allergenic, inflammatory or other undesirable effect, and it avoids mechanical contact with the eye surface.

Abstract: The present invention relates to micro-sized particles having anti-biocontaminant properties. Each particle is comprised of a central metal core, or support structure, (for example, alumina oxide) and has on its surface, one or more anti-biocontaminant metals and at least one redox agent.

Abstract: A depilatory kit may comprise a depilatory composition comprising a sulfur-containing depilatory agent and a finishing composition comprising a metal oxide selected from the group consisting of zinc oxide, aluminum oxide, and magnesium oxide. The depilatory composition may further comprise a lactone such as 1,15-cyclopentadecanolide. Methods for using the depilatory kits are also disclosed herein.

Abstract: Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.

Abstract: The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1 antagonists to effect localized treatment.

Abstract: This disclosure relates to inventive methods for inactivating viral pathogens comprising providing a virucidal composition comprising a liquid media containing less than 1% weight per volume of a quaternary ammonium compound, such as cetylpyridinium chloride and between 0% and 0.5% weight per volume of citric acid, and contacting a surface targeted for disinfection with the virucidal composition. This disclosure further relates to inventive virucidal compositions comprising a liquid media, a quaternary ammonium compound, such as cetylpyridinium chloride, at a concentration of less than 1% weight per volume, citric acid at a concentration of between 0.0% and 0.5% weight per volume, an extender, and an enhancer.

Abstract: Disclosed is an anticancer or an antiviral composition comprising therapeutically effective amounts of citric acid and or zinc and L-arginine along with a pharmaceutically acceptable carrier. The anticancer composition of the present invention has a strong anticancer effect while not having harmful side effects. The antiviral compositions of the present invention is useful for treatment of diseases caused by viral infections.

Abstract: A micronutrient dosage unit which comprises two or more micronutrients selected from vitamin A, vitamin B2, vitamin B6, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, calcium, magnesium, zinc, boron and chromium in one or more specified ratios. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

Abstract: The present invention relates to compositions and methods for preventing and treating osteochondrosis by administration of supplemental boron containing compounds to animals and humans. The supplemental boron containing compounds are provided in animal feed compositions or as supplements for animal feed. Also provided by this invention are animal feed compositions that are supplemented with boron containing compounds and which have reduced phosphorus content. The invention also provides a method for treating or preventing osteochondrosis in animals or humans by the administration of supplemental boron containing compounds. The invention also provides a method for decreasing the amount of phosphorus excreted by an animal, a method of increasing the efficiency of absorption of phosphorus by an animal, a method of reducing environmental phosphorus pollution by administering supplemental boron to the animal.

Abstract: This invention relates to high surface area materials, such as nanoparticles, that are coated with metal ions. These modified nanoparticles have active sites that bind various gases and/or odorous compounds, thereby removing these compounds from a medium such as air or water. Metal ions are adsorbed onto the surface of the nanoparticle and bound strongly to the surface. By selection of the metal ion, specific gaseous compounds and/or odorous compounds can be targeted and removed efficiently and effectively from both aqueous phase and from the air. The modified nanoparticles are useful in numerous article of manufacture for industrial and consumer use.

Abstract: A method of treating cancer. The method includes introducing an effective amount of an oxidative catalyzing agent including titanium oxide, zinc oxide, zirconium oxide, tungsten oxide or tin oxide into a biological entity, and irradiating the biological entity with a ray. The oxidative catalyzing agent produces hydroxyl or hydrogen peroxide radicals after irradiation with the ray thereon.

Abstract: The present disclosure relates, according to some embodiments, to antimicrobial agents comprising nitric acid, tetraethylorthosilicate, tetraethyl phosphate, zinc nitrate, and gallium nitrate. Antimicrobial agents may also include borane-tert-butylamine. Antimicrobial agents restrict and/or prevent the growth of at least one bacteria and/or at least one fungus. Bacteria may include, for example, Actinomyetes (e.g., Nocardia), Salmonella, Escherichia, Staphylococcus (e.g., Staphylococcus Aureus), Enterobacter (e.g., Enterobacter aerogenes), and/or Bacillus. Fungi may include, for example, Stachybotrys, Fusarium, Aspergillus (e.g., Aspergillus flavus), Penicillium, Candida (e.g., Candida albicans), Paracoccidiodes, and/or Trycophyton.

Abstract: Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to provide biologically available fluoride ions to the tooth tissue being treated. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors.

Abstract: Use, method of manufacturing a pharmaceutical composition, pharmaceutical composition for the treatment of skin ailments comprising a therapeutic quantity in aqueous solution of nitric acid of 5 to 15 mmol/ml of pharmaceutical composition, and also comprising a zinc salt at a concentration of 0.01 to 0.015 mg of Zn2+ ions/ml as well as a copper salt at a concentration of 0.01 to 0.015 mg of Cu2+ ions/ml of pharmaceutical composition and its medical device.

Abstract: The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts to prevent the irritation of skin or mucous membranes that may be caused by therapeutic agents, by personal hygiene products, or by various physical, chemical, mechanical, or biological irritants, including infectious agents.

Abstract: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in subjects undergoing physiologically stressful events, such as, for example and without limitation, pregnancy, lactation or any disease state.

Abstract: This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).

Abstract: The present invention disclosed a composition for enhancing immune function comprising, as active ingredients, zinc and a saccharide having 3-O-?-D-glucopyranosyl-D-glucose as a structural unit. The composition for enhancing immune function according to the present invention exhibits a remarkably superior immunoenhancing effect to that achieved by the independent use of zinc and a saccharide having 3-O-?-D-glucopyranosyl-D-glucose as a structural unit.

Abstract: The present invention relates to synergistic associations of melatonin and other active substances and cosmetic compositions suitable for treating all those manifestations causing or accompanying the aging of skin, hair and other tissues. In particular, the invention is based on the use of melatonin associated with immunoactive and antioxidant substances significantly potentiating its antiaging activity, remarkably reducing free radical formation and thereby improving the aspect of both skin and hair.

Abstract: Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity.

Abstract: This invention relates to a non-medicinal food additive that is an animal growth promoter containing 99% pure zeolite partially or totally exchanged with a Cm+ cation, i.e., a synthetic zeolite, having the general formula I below: 1 m ? yC m + ? ( 1 - y ) ? 1 n ? M n + ? AlO 2 ? xSiO 2 in which x is greater than 1 and advantageously between 1 and 15; Mn+ represents an alkaline or alkaline earth exchangeable ion, advantageously Na+, K+, Ca2+ or Li+; n is between 1 and 2; y is the exchange rate and is between 0.001 and 1; Cm+ is a metallic cation chosen from among copper Cu2+, silver Ag+ or zinc Zn2+; m is between 1 and 2; this invention also relates to an additive premix and a supplemented food containing same and a method of improving the growth of animals.

Abstract: Compositions and methods are provided for treating wood products to provide leach-resistant protection against fungal decay, termites and other wood destroying organisms. The preservative compositions provided include ammonia-stabilized solutions of zinc and boron, preferably in a molar ratio of Zn:B of between about 0.4:1 and 5:1, and are essentially copper free. The preservative may be applied by vacuum and/or pressure treatment or dip treatment under atmospheric pressure.

Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

Abstract: Biocide compositions capable of increasing the fading resistance of a coating material, which compositions preferably comprise a nano-sized halogenated benzonitrile and a nano-sized zinc oxide, are disclosed. Coating compositions, which comprise the biocide compositions, binders, and pigments are disclosed. The biocide compositions are particularly suitable for use in paints. Methods for reducing the fading of pigmented coating compositions upon exposure to light are also disclosed.

Abstract: The use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood.

Abstract: Here we disclose the response of normal human cells to ZnO nanoparticles under different signaling environments and compare it to the response of cancerous cells. ZnO nanoparticles exhibit a strong preferential ability to kill cancerous T cells (˜28-35X) compared to normal cells. Interestingly, the activation state of the cell contributes toward nanoparticle toxicity as resting T cells display a relative resistance while cells stimulated through the T cell receptor and CD28 costimulatory pathway show greater toxicity in direct relation to the level of activation. The novel findings of cell selective toxicity towards potential disease causing cells indicate a potential utility of ZnO nanoparticle in the treatment of cancer and/or autoimmunity.

Abstract: Two-phase preparation for temporally gradual administration comprising a) a phase (A) comprising water soluble vitamins and/or the corresponding provitamins, wherein phase (A) does not contain liposoluble vitamins or provitamins corresponding to liposoluble vitamins, b) a phase (B) comprising vitamins and/or the corresponding provitamins, wherein the quantity of liposoluble vitamin compounds is larger than the quantity of water soluble vitamin compounds.

Abstract: A set of signature genes that predict the severity of septic shock, as well as methods of diagnosing and treating septic shock. The genes and methods are particularly useful for the identification of individuals who are at a high risk of death from septic shock.

Abstract: The invention relates to biologically active nanoparticles of a carbonate-substituted non-stoichiometric hydroxyapatite, having: a) a crystallinity degree CD lower than 40%, the crystallinity degree being defined as CD=(1?X/Y)·100 wherein: Y=height of the diffraction maximum at 2?=33°, X=height of the diffraction background at 2?=33° of the nanoparticles X-ray diffraction pattern; b) a length L ranging from 20 to 200 nm and a width W ranging from 5 to 30 nm; and c) an aspect ratio AR comprised between 2 and 40, the aspect ratio being defined as AR=L/W. The biologically active nanoparticles of the invention find a preferred use in oral or dental hygiene applications and may be formulated as compositions for oral or dental hygiene such as, for example, solutions, suspensions, oils, gels or other solid products.

Abstract: The present invention provides macrolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram-positive, gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Propionibeacterium, Bacillus, Enterobactericeae or any combination thereof. Also provided are processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods of treating bacterial infections.

Abstract: Novel preparations comprising branched ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The preparations have a prolonged action designed for flexible injection regimes.

Abstract: The present invention provides compositions and methods for decreasing photosensitivity induced by photodynamic therapy (PDT). The compositions and methods of the present method employ porphyrin complexing molecules as agents for reducing photosensitivity.

Abstract: The invention is directed to methods and compositions for preparing matrices for controlled delivery of at least one therapeutic or biological agent to a target site in a subject. This is accomplished using nanoparticles coupled to the therapeutic or biological agent that are incorporated within the matrix or reacted on the surface of the matrix.

Abstract: A material for the treatment or prophylaxis of microbial, including bacterial, infections, comprising a metal species and a polymer, wherein the polymer stabilises the metal species. Compositions and devices comprising the material. A method for the treatment or prophylaxis of microbial, including bacterial, infections, comprising the use of such a material, composition or device.

Abstract: This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).

Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.

Abstract: There is provided a method for treating a fluid with an anti-microbial agent comprising the steps of: (a) contacting the fluid with a solid material containing an anti-microbial agent; and, (b) abrading an interface of the solid material and removing particles therefrom and exposing an underlying surface of the solid material to the fluid, thereby facilitating release of the antimicrobial agent of the underlying surface of the solid material and/or the removed particles into the fluid. The solid material comprises an anti-microbial agent dispersed and/or embedded in a solid carrier. Typically, the anti-microbial agent is one or more of a metal, metal oxide, metal compound, metal salt, metal-ligand complex or derivatives thereof based on silver, copper and zinc.

Abstract: A vitreous antimicrobial agent that can exhibit excellent antimicrobial properties when added to various types of resins, that has excellent discoloration resistance and hot water resistance, and that can easily be produced at a commercial scale. The vitreous antimicrobial agent includes, relative to 100 mass % of total glass components, 0.1 to 2 mass % of Ag2O, 40.5 to 49 mass % of ZnO, 6 to 9.5 mass % of SiO2, 30.5 to 39.5 mass % of B2O3, 2 to 10 mass % of an alkaline earth metal oxide, and 6 to 7.5 mass % of Na2O; the vitreous antimicrobial agent comprising, in addition to these, 0.01 to 5 mass % of CeO2 as necessary. An antimicrobial resin composition and an antimicrobial product including the vitreous antimicrobial agent.

Abstract: The present invention relates to a method for the preparation of reverse micelles based on sterols, acylglycerols and metal salt and to reverse micelles obtained thereby. They are advantageously useful in the pharmaceutical and dietetic fields.

Abstract: Compositions and methods are provided that are based on a discovery that a combination of three compounds, doxycycline, selenium, and zinc, retards physiological age-related changes (for example cardiac aging and the decline in exercise capacity) and can also prolong survival.

Abstract: Aspects of the invention include a sustained release dosage form that can be administered to an oral cavity, e.g., the mouth. In certain embodiments, the sustained release dosage form is formulated as a lozenge or gum that may be administered to an oral cavity of a user for the purpose of dissolving over a prolonged period of time and thereby delivering an essential oil component therein. In certain embodiments, the sustained release dosage form includes a beneficial agent and, therefore, not only provides for the prolonged delivery of an essential oil component to an oral cavity, but also provides for the sustained release of a beneficial agent thereto. In certain embodiments, the sustained release dosage form includes a biocompatible, water-insoluble polymer, e.g.

Abstract: A method of increasing pregnancy rate in a female subject is provided, the female subject or an oocyte for introduction into the female subject being fertilized by a sperm from a male subject. The method includes the steps of administering to the male subject prior to fertilization: (i) an effective amount of an anti-oxidant agent; and (ii) an effective amount of an agent that reduces inflammation in the male reproductive tract and/or an effective amount of an agent that increases testicular testosterone concentration.

Abstract: Novel magnesium-based compositions-of-matter which can be used for manufacturing implantable medical devices such as orthopedic implants are disclosed. The compositions-of-matter can be used for constructing monolithic, porous and/or multilayered structures which are characterized by biocompatibility, mechanical properties and degradation rate that are highly suitable for medical applications. Articles, such as medical devices, made of these magnesium-based compositions-of-matter and processes of preparing these magnesium-based compositions-of-matter are also disclosed.

Abstract: The invention is related to insulin compositions with a high content of zinc atoms per six molecules of acylated insulin. The insulin is an acylated insulin and may be mixed with a further insulin analogue such as the rapid acting insulin Asp B28 human insulin.

Abstract: The present invention provides novel biomaterials comprising one or more of Mg, Zn and F ions in a carbonate-containing biphasic calcium phosphate (BCP) system. The biomaterial may contain Mg, Zn, F, Mg and Zn, Mg and F, Zn and F, or Mg, Zn and F. The biomaterial may be substantially similar in composition to bone mineral (a carbonate apatite). The biomaterial may feature slow release of Mg, Zn, F, Ca, and P ions. The biphasic calcium phosphate, BCP, may be a mixture of unsubstituted hydroxyapatite (HA) and unsubstituted .-TCP, Ca3(PO4)2. BCP of varying HA/.-TCP ratios may be produced by sintering calcium-deficient apatite, for instance having a Ca/P<1.5, 1.6, 1.67, 1.75 or 1.8 that has been prepared either by a precipitation or by a hydrolysis method or by a solid-state reaction. The amount of each component (by weight %) present in the biomaterials may be as follows: Mg 0.5 to 12 wt %, Zn 1 to 12 wt %, F 0.1 to 4 wt %, calcium 20 to 40 wt %, phosphate 10 to 20 wt %, and carbonate (CO3) 1 to 20 wt %.

Abstract: Combinations of a polyunsaturated fatty acid and diindolylmethane and pharmaceutical composition containing such combinations. Further provided are combinations including a polyunsaturated fatty acid, diindolylmethane, and folic acid. Also provided are combinations including diindolylmethane and folic acid. Also provided is a method for increasing the number of normal cells and decreasing the number of aberrant cells in a subject having the steps of administering to the subject a combination comprising a polyunsaturated fatty acid and diindolylmethane.